Fexapotide triflutate FDA Approval Status
FDA Approved: No
Generic name: fexapotide triflutate
Previous Name: NX-1207
Company: Nymox Pharmaceutical Corporation
Treatment for: Benign Prostatic Hyperplasia
Fexapotide triflutate is an injectable pro-apoptotic agent in development for the treatment of benign prostatic hyperplasia.
Development Timeline for fexapotide triflutate
|Feb 5, 2018||Nymox Announces US NDA for Fexapotide for BPH|
|Jan 30, 2018||Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.